Posted by Michael Wonder on 11 Mar 2021
Astellas submits new drug application for enfortumab vedotin in Japan
11 March 2021 - Enfortumab vedotin to be reviewed by Ministry of Health, Labour and Welfare for patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication
Astellas today announced the submission of a new drug application to Japan's Ministry of Health, Labour and Welfare for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication.
